These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 32431173)

  • 21. Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency.
    Chaudhry C
    J Med Chem; 2023 May; 66(9):6239-6250. PubMed ID: 37102218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
    Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
    Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    Setia N; Almuqdadi HTA; Abid M
    Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
    Coll-Martínez B; Delgado A; Crosas B
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted protein degradation and the enzymology of degraders.
    Fisher SL; Phillips AJ
    Curr Opin Chem Biol; 2018 Jun; 44():47-55. PubMed ID: 29885948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted Protein Degradation: Design Considerations for PROTAC Development.
    Tran NL; Leconte GA; Ferguson FM
    Curr Protoc; 2022 Dec; 2(12):e611. PubMed ID: 36469581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemically induced degradation of epigenetic targets.
    Kabir M; Yu X; Kaniskan HÜ; Jin J
    Chem Soc Rev; 2023 Jul; 52(13):4313-4342. PubMed ID: 37314393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
    Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
    Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recognition of substrate degrons by E3 ubiquitin ligases and modulation by small-molecule mimicry strategies.
    Lucas X; Ciulli A
    Curr Opin Struct Biol; 2017 Jun; 44():101-110. PubMed ID: 28130986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small-molecule PROTACs: novel agents for cancer therapy.
    Wan Y; Yan C; Gao H; Liu T
    Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted protein degradation via intramolecular bivalent glues.
    Hsia O; Hinterndorfer M; Cowan AD; Iso K; Ishida T; Sundaramoorthy R; Nakasone MA; Imrichova H; Schätz C; Rukavina A; Husnjak K; Wegner M; Correa-Sáez A; Craigon C; Casement R; Maniaci C; Testa A; Kaulich M; Dikic I; Winter GE; Ciulli A
    Nature; 2024 Mar; 627(8002):204-211. PubMed ID: 38383787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Native Mass Spectrometry Can Effectively Predict PROTAC Efficacy.
    Beveridge R; Kessler D; Rumpel K; Ettmayer P; Meinhart A; Clausen T
    ACS Cent Sci; 2020 Jul; 6(7):1223-1230. PubMed ID: 32724856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. E3 ligase ligand chemistries: from building blocks to protein degraders.
    Sosič I; Bricelj A; Steinebach C
    Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization.
    Schwalm MP; Krämer A; Dölle A; Weckesser J; Yu X; Jin J; Saxena K; Knapp S
    Cell Chem Biol; 2023 Jul; 30(7):753-765.e8. PubMed ID: 37354907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
    Zeng S; Huang W; Zheng X; Liyan Cheng ; Zhang Z; Wang J; Shen Z
    Eur J Med Chem; 2021 Jan; 210():112981. PubMed ID: 33160761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A modular PROTAC design for target destruction using a degradation signal based on a single amino acid.
    Shanmugasundaram K; Shao P; Chen H; Campos B; McHardy SF; Luo T; Rao H
    J Biol Chem; 2019 Oct; 294(41):15172-15175. PubMed ID: 31511327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteolysis-targeting chimeras for targeting protein for degradation.
    Qi J; Zhang G
    Future Med Chem; 2019 Apr; 11(7):723-741. PubMed ID: 30706727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution.
    Xiao Y; Yuan Y; Liu Y; Lin Z; Zheng G; Zhou D; Lv D
    J Med Chem; 2024 Jul; 67(14):11580-11596. PubMed ID: 38981094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.